siltuximab + bortezomib + melphalan + prednisone

Siltuximab + bortezomib + melphalan + prednisone is a combination regimen studied for the treatment of newly diagnosed multiple myeloma, particularly in patients ineligible for autologous stem cell transplantation. - **Siltuximab** is a chimeric monoclonal antibody that binds interleukin-6 (IL-6), a cytokine involved in the proliferation and survival of malignant plasma cells. By blocking IL-6, siltuximab aims to reduce tumor growth and enhance sensitivity to cytotoxic agents[1][6]. - **Bortezomib** is a small molecule proteasome inhibitor that disrupts protein degradation, leading to apoptosis in myeloma cells[1]. - **Melphalan** is an alkylating agent that cross-links DNA, leading to cytotoxicity and cell death[1]. - **Prednisone** is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive effects, helping reduce myeloma cell burden[1]. This regimen has been evaluated in phase 2 clinical trials for transplant-ineligible patients with newly diagnosed multiple myeloma. While siltuximab improved very good partial responses, it did not significantly increase complete response rates, progression-free survival, or overall survival when added to bortezomib-melphalan-prednisone[1][5][6].

Brand names

Deltacortril

Other names

S+VMPsiltuximab plus bortezomib-melphalan-prednisone